Literature DB >> 30366717

[Diagnostic and therapeutic recommendations for sexually transmitted diseases: Genital herpes].

B Milpied1, M Janier2, J Timsit2, N Spenatto3, E Caumes4, O Chosidow5, L Sentilhes6, M-V Senat7.   

Abstract

TREATMENT OF THE INITIAL INFECTION OR FIRST CLINICAL EPISODE OF GENITAL HERPES: An initial infection or first clinical episode of genital herpes is treated with oral aciclovir 200mg×5/d for 5 to 10 days depending on clinical status. The recommended dosage for valaciclovir is 1g×2/d and treatment duration is identical to that for aciclovir. TREATMENT OF HERPES RECURRING DURING PREGNANCY: There are no studies of the efficacy of antiviral therapy on the symptoms of genital recurring during pregnancy. However, initial anti-viral treatment using aciclovir or valaciclovir may be given where warranted by symptoms (i.e. duration and severity of symptoms). Valaciclovir may be used instead (equivalent efficacy but better safety data for aciclovir). Valaciclovir may be given at a dosage of 1×500mg b.i.d. p.o. for 5 days. PROPHYLACTIC ANTI-VIRAL TREATMENT DURING PREGNANCY: In female patients presenting an initial infection or infection recurring during pregnancy, although there is no demonstrated benefit for prophylactic treatment in reducing the risk of neonatal herpes, anti-viral prophylaxis is recommended after 36 WA (weeks' amenorrhoea) to limit the need for Caesarean section due to herpetic lesions. The recommended antivirals are aciclovir at a dosage of 400mg t.i.d p.o. or valaciclovir at a dosage of 500mg b.i.d. p.o. until delivery.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aciclovir; Femme enceinte; Genital herpes; Grossesse; HSV; Herpès génital; Pregnancy; Valaciclovir

Mesh:

Substances:

Year:  2018        PMID: 30366717     DOI: 10.1016/j.annder.2018.07.029

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  1 in total

1.  Autoimmune hypophysitis and viral infection in a pregnant woman: a challengeable case.

Authors:  Kais Benabderrahim
Journal:  Pan Afr Med J       Date:  2020-05-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.